The risk of relapse in papillary thyroid cancer (PTC) in the context of BRAFV600E mutation status and other prognostic factors

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Czarniecka, Agnieszka ^a   Kowal, Monika ^a   Rusinek, Dagmara ^a   Krajewska, Jolanta ^a   Jarzab, Michal ^a   Stobiecka, Ewa ^a   Chmielik, Ewa ^a   Zembala Nozynska, Ewa ^a   Poltorak, Stanislaw ^a   Sacher, Aleksander ^a   Maciejewski, Adam ^a   Zebracka Gala, Jadwiga ^a   Lange, Dariusz ^a   Oczko Wojciechowska, Malgorzata ^a   Handkiewicz Junak, Daria ^a   Jarzab, Barbara ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; IODINE 131; BRAF PROTEIN, HUMAN; GLUTAMIC ACID; TUMOR MARKER; VALINE;

ADULT; AGE; ARTICLE; CANCER INFILTRATION; CANCER PROGNOSIS; CANCER RECURRENCE; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NECK DISSECTION; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TUMOR INVASION; TUMOR VOLUME; YOUNG ADULT; AMINO ACID SUBSTITUTION; CARCINOMA; GENE FREQUENCY; GENETICS; MISSENSE MUTATION; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RECURRENT DISEASE; RISK FACTOR; THYROID NEOPLASMS;

ADULT; AMINO ACID SUBSTITUTION; BIOMARKERS, TUMOR; CARCINOMA; FEMALE; GENE FREQUENCY; GLUTAMIC ACID; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RECURRENCE; RISK FACTORS; THYROID NEOPLASMS; VALINE;

EID: 84941338341     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132821     Document Type: Article

References (58)

1. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013; 13:184-99. doi: 10.1038/nrc3431 PMID: 23429735
2. Puxeddu E, Filetti S. BRAF mutation assessment in papillary thyroid cancer: are we ready to use it in clinical practice? Endocrine. 2014; 45:341-3. doi: 10.1007/s12020-013-0139-0 PMID: 24366644
3. Aschebrook-Kilfoy B, Schechter RB, Shih Y-CT, Kaplan EL, Chiu BC-H, Angelos P, et al. The clinical and economic burden of a sustained increase in thyroid cancer incidence. Cancer Epidemiol Biomarkers Prev. 2013; 22:1252-9. doi: 10.1158/1055-9965.EPI-13-0242 PMID: 23677575
4. Didkowska J., Wojciechowska U. ZW. Cancer in Poland in 2011. Polish Natl Cancer Regist Warsaw. 2013;http://onk:54:56
5. Howell GM, Nikiforova MN, Carty SE, Armstrong MJ, Hodak SP, Stang MT, et al. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol. 2013; 20:47-52. doi: 10.1245/s10434-012-2611-0 PMID: 22941165
6. Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer. 2012; 118:1764-73. doi: 10.1002/cncr.26500 PMID: 21882184
7. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh Q-Y, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007; 246:466-70; discussion 470-1. doi: 10. 1097/SLA.0b013e318148563d PMID: 17717450
8. Howell GM, Carty SE, Armstrong MJ, Lebeau SO, Hodak SP, Coyne C, et al. Both BRAF V600E mutation and older age (65 years) are associated with recurrent papillary thyroid cancer. Ann Surg Oncol. 2011; 18:3566-71. doi: 10.1245/s10434-011-1781-5 PMID: 21594703
9. Alzahrani AS, Xing M. Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND. Endocr Relat Cancer. 2013; 20:13-22. doi: 10.1530/ERC-12-0309 PMID: 23132792
10. Ahn D, Park JS, Sohn JH, Kim JH, Park S-K, Seo AN, et al. BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma. Auris Nasus Larynx. 2012; 39:198-203. doi: 10.1016/j.anl.2011.07.011 PMID: 21862261
11. Kurtulmus N, Duren M, Ince U, Cengiz Yakicier M, Peker O, Aydin O, et al. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Endocrine. 2012; 42:404-10. doi: 10.1007/s12020-012-9651-x PMID: 22426956
12. Pelizzo MR, Dobrinja C, Casal Ide E, Zane M, Lora O, Toniato A, et al. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma. Biomed Pharmacother. 2014; 68:413-7. doi: 10.1016/j.biopha.2014.03.008 PMID: 24721322
13. Joo J-Y, Park J-Y, Yoon Y-H, Choi B, Kim J-M, Jo YS, et al. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study. J Clin Endocrinol Metab. 2012; 97:3996-4003. doi: 10.1210/jc.2012-2444 PMID: 22930785
14. Xing M. BRAF mutation in papillary thyroid microcarcinoma: the promise of better risk management. Ann Surg Oncol. 2009; 16:801-3. doi: 10.1245/s10434-008-0298-z PMID: 19159982
15. Danilovic DLS, Lima EU, Domingues RB, Brandão LG, Hoff AO, Marui S. Pre-operative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma. Eur J Endocrinol. 2014; 170:619-25. doi: 10.1530/EJE-13-0944 PMID: 24468978
16. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013; 381:1058-69. doi: 10.1016/S0140-6736(13)60109-9 PMID: 23668556
17. Handkiewicz-Junak D, Czarniecka A, Jarzab B. Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. Mol Cell Endocrinol. 2010; 322:8-28. doi: 10.1016/j.mce.2010.01.007 PMID: 20138116
18. Nam JK, Jung CK, Song BJ, Lim DJ, Chae BJ, Lee NS, et al. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? Am J Surg. 2012; 203:436-41. doi: 10.1016/j. amjsurg.2011.02.013 PMID: 21803329
19. Xing M, Clark D, Guan H, Ji M, Dackiw A, Carson KA, et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol. 2009; 27:2977-82. doi: 10.1200/JCO.2008.20.1426 PMID: 19414674
20. Li C, Aragon Han P, Lee KC, Lee LC, Fox AC, Beninato T, et al. Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers. J Clin Endocrinol Metab. 2013; 98:3702-12. doi: 10.1210/jc.2013-1584 PMID: 23969188
21. Niederer-Wüst SM, Jochum W, Förbs D, Brändle M, Bilz S, Clerici T, et al. Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer. Surgery. 2015; 157:119-125. doi: 10.1016/j.surg.2014.07.015 PMID: 25482468
22. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab. 2008; 93:3943-9. doi: 10.1210/jc.2008-0607 PMID: 18682506
23. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005; 90:6373-9. doi: 10.1210/jc.2005-0987 PMID: 16174717
24. Cho BY, Choi HS, Park YJ, Lim JA, Ahn HY, Lee EK, et al. Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades. Thyroid. 2013; 23:797-804. doi: 10.1089/thy.2012.0329 PMID: 23427907
25. Russo M, Malandrino P, Nicolosi ML, Manusia M, Marturano I, Trovato MA, et al. The BRAF(V600E) Mutation Influences the Short-and Medium-Term Outcomes of Classic Papillary Thyroid Cancer, But Is Not an Independent Predictor of Unfavorable Outcome. Thyroid. 2014; 24(8):1267-74 doi: 10.1089/thy.2013.0675 PMID: 24787545
26. Mond M, Alexiadis M, Fuller PJ, Gilfillan C. Mutation profile of differentiated thyroid tumours in an Australian urban population. Intern Med J. 2014; 44(8):727-34 doi: 10.1111/imj.12476 PMID: 24862939
27. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013; 309:1493-501. doi: 10.1001/jama.2013.3190 PMID: 23571588
28. Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, et al. Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer. J Clin Oncol. 2015; 33(1):42-50 doi: 10. 1200/JCO.2014.56.8253 PMID: 25332244
29. Czarniecka A, Rusinek D, Stobiecka E, Krajewska J, Kowal M, Kropinska A, et al. Occurrence of BRAF mutations in a Polish cohort of PTC patients - Preliminary results. Endokrynol Pol. 61:462-6. PMID: 21049459
30. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf). 2006; 65:364-8. doi: 10.1111/j.1365-2265.2006.02605.x
31. Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, et al. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab. 2012; 97:4390-8. doi: 10.1210/jc.2012-1775 PMID: 23066120
32. Kim J, Giuliano AE, Turner RR, Gaffney RE, Umetani N, Kitago M, et al. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg. 2006; 244:799-804. doi: 10.1097/01.sla.0000224751.80858.13 PMID: 17060774
33. Xing M. Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol. 2010; 321:86-93. doi: 10.1016/j.mce.2009.10.012 PMID: 19883729
34. Virk RK, Van Dyke AL, Finkelstein A, Prasad A, Gibson J, Hui P, et al. BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation. Mod Pathol. 2013; 26:62-70. doi: 10. 1038/modpathol.2012.152 PMID: 22918165
35. Choi SY, Park H, Kang MK, Lee DK, Lee KD, Lee HS, et al. The relationship between the BRAF (V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors. World J Surg Oncol. 2013; 11:291. doi: 10.1186/1477-7819-11-291 PMID: 24228637
36. Walczyk A, Kowalska A, Kowalik A, Sygut J, Wypiórkiewicz E, Chodurska R, et al. The BRAF(V) (600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome? Clin Endocrinol (Oxf). 2014; 80:899-904. doi: 10.1111/cen.12386
37. Kim S, Lee KE, Myong JP, Park J, Jeon YK, Min HS, et al. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg. 2012; 36:310-7. doi: 10.1007/s00268-011-1383-1 PMID: 22190222
38. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf). 2005; 63:588-93. doi: 10.1111/j.1365-2265.2005.02389.x
39. Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J. 2009; 56:89-97. PMID: 18840924
40. Barbaro D, Incensati RM, Materazzi G, Boni G, Grosso M, Panicucci E, et al. The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis. Endocrine. 2014; 45:462-8. doi: 10.1007/s12020-013-0029-5 PMID: 23925579
41. Pacini F, Castagna MG, Brilli L, Pentheroudakis G. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23 Suppl 7:vii110-9. doi: 10.1093/annonc/mds230 PMID: 22997443
42. Jarzab B, Sporny S, Lange D,Wloch J, Lewinski A, Baldys-Waligórska A, et al. [Diagnosis and treatment of thyroid cancer - Polish guidelines]. Endokrynol Pol. 2010; 61:518-68 PMID: 21049469
43. Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19:1167-214. doi: 10.1089/thy.2009.0110 PMID: 19860577
44. Watkinson JC. The British Thyroid Association guidelines for the management of thyroid cancer in adults. Nucl Med Commun. 2004; 25:897-900 PMID: 15319594
45. Randolph GW1, Duh QY, Heller KS, LiVolsi VA, Mandel SJ, Steward DL, et al. American Thyroid Association Surgical Affairs Committee's Taskforce on Thyroid Cancer Nodal Surgery. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012; 22 (11):1144-52 doi: 10.1089/thy.2012.0043 PMID: 23083442
46. Chakraborty A, Narkar A, Mukhopadhyaya R, Kane S, D'Cruz A, Rajan MGR. BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion. Endocr Pathol. 2012; 23:83-93. doi: 10.1007/s12022-011-9184-5 PMID: 22105775
47. Bernstein J, Virk RK, Hui P, Prasad A, Westra WH, Tallini G, et al. Tall cell variant of papillary thyroid microcarcinoma: clinicopathologic features with BRAF(V600E) mutational analysis. Thyroid. 2013; 23:1525-31. doi: 10.1089/thy.2013.0154 PMID: 23682579
48. Czarniecka A, Poltorak S, Sacher A, Maciejewski A, Krajewska J, Jarzab M, et al. Surgical strategy in low advanced differentiated thyroid cancer staged T1N0M0-results of a pilot feasibility study. Eur Thyroid J. 2014; 3:104
49. Carling T, Carty SE, Ciarleglio MM, Cooper DS, Doherty GM, Kim LT, et al. American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. Thyroid. 2012; 22:237-44. doi: 10.1089/thy.2011.0317 PMID: 22313454
50. Lee J-H, Lee E-S, Kim Y-S. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer. 2007; 110:38-46. doi: 10.1002/cncr.22754 PMID: 17520704
51. Li C, Lee KC, Schneider EB, Zeiger MA. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab. 2012; 97:4559-70. doi: 10.1210/jc.2012-2104 PMID: 23055546
52. Song F, Parekh S, Hooper L, Loke YK, Ryder J, Sutton AJ, et al. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess. 2010; 14:iii, ix-xi, 1-193. doi: 10.3310/hta14080
53. Matosin N, Frank E, Engel M, Lum JS, Newell KA. Negativity towards negative results: a discussion of the disconnect between scientific worth and scientific culture. Dis Model Mech. 2014; 7:171-3. doi: 10. 1242/dmm.015123 PMID: 24713271
54. Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, et al. BRAF V600E and TERT Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer With Highest Recurrence. J Clin Oncol. 2014; doi: 10.1200/JCO.2014.55.5094
55. Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, et al. TERT Promoter Mutations and Their Association with BRAF V600E Mutation and Aggressive Clinicopathological Characteristics of Thyroid Cancer. J Clin Endocrinol Metab. 2014; 99:E1130-6. doi: 10.1210/jc.2013-4048 PMID: 24617711
56. Huang Y, Liao D, Pan L, Ye R, Li X, Wang S, et al. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation. Eur J Endocrinol. 2013; 168:675-81. doi: 10.1530/EJE-12-1029 PMID: 23416953
57. Sun Y, Yu S, Liu Y, Wang F, Liu Y, Xiao H. Expression of miRNAs in Papillary Thyroid Carcinomas Is Associated with BRAF Mutation and Clinicopathological Features in Chinese Patients. Int J Endocrinol. 2013; 2013:128735. doi: 10.1155/2013/128735 PMID: 23690767
58. Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, Pai S, Bishop J. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014 Sep 1; 32(25):2718-26 doi: 10.1200/JCO.2014.55.5094 PMID: 25024077